2017_IGRT course book

Phase I Results—Clinical Outcomes

No Grade 3 toxicity at median 11.8 mo f/u Expected 20-30% using aggressive dose regimen No change in patient- reported EORTC-qlq 30 QOL scores ( P = 0.29) at 0, 6, and 12wks.

Mean EORTC-30 QOL Score

80

70

60

50

40

30

Quality of Life Score

20

10

0

0

6

12

Time Since Completion of Therapy (weeks)

Henke et al, ASTRO 2016

ESTRO IG and Adaptive Course Parikh 02.11.2017